Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.

Pills and tablets

On 8 March 2018, the London School of Hygiene & Tropical Medicine (LSHTM) announced the start of a major new global study, the 4-year Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE) project.

By identifying the leading causes of fever in sub-Saharan Africa and Asia and how fever patients are cared for, FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.

Funded by UKAid from DFID, FIEBRE will be conducted by LSHTM with the Liverpool School of Tropical Medicine, the Universities of Oxford, Barcelona, and Otago, as well as partner institutions within five study countries – Laos, Malawi, Mozambique, Myanmar and Zimbabwe.

MORU’s Lao PDR Unit, LOMWRU, and the Microbiology Laboratory team within Mahosot Hospital, Vientiane, will work with Vientiane Provincial Hospital for the Laos arm of this multicentre study. In addition, Yoel Lubell of MORU MAEMOD will coordinate the biomarker investigations, so that by its end, the study will have a better idea as to which biomarkers best distinguish between viral and bacterial infections, and which (if any) can predict severe outcomes.

“There is an urgent need to understand the aetiologies of fevers across Asia and Africa with consensus protocols to facilitate between country comparisons, that have so far eluded us, to inform patient treatment policies,” explained Oxford Prof Paul Newton, LOWMRU Director. “We will work to recruit and diagnose inpatients and outpatients to improve our understanding of the causes of fever in the Mekong River valley and how these compare with other countries and to work for these results to be translated into health policy.”

David Mabey, Professor of Communicable Diseases at the LSHTM and Principal Investigator of the FIEBRE project, said: “The world has made great strides in tackling malaria. Surprisingly, there has been limited research on other potential causes of febrile illness, such as infections by bacteria, viruses, and fungi, and the WHO does not provide specific guidance on the management of non-malarial fevers.

“We want to identify the treatable and preventable causes of fever in children and adults in Africa and Asia, and to identify those most at risk of different infections. Our goal is to develop guidelines that can be a blueprint for the effective management of patients with fever in different settings.”

Read the full LSHTM story announcing the FIEBRE study Major new project to reveal leading causes of fever in sub-Saharan Africa and Asia.

Similar stories

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.